In animal models of colorectal, lung and skin cancer, treatment with anti-PD-L1 (Programmed cell death-ligand 1) therapy at the beginning of the behavioral active phase—compared with the rest phase—elicited a greater antitumor immune response measured by a larger increase in intratumor CD8+T and myeloid-derived suppressor cells. This evidence concerns the gene CD274 and skin neoplasm.